- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00058045
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
A Phase I Study Of Low-Dose Subcutaneous Interleukin 2 (IL-2) And Stem Cell Factor (r-metHuSCF) For Patients With AIDS And AIDS-Associated Malignancy
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of cancer therapy.
PURPOSE: Phase I trial to study the effectiveness of combining interleukin-2 with stem cell factor in treating patients who have AIDS or AIDS-related cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the safety and toxicity of low-dose interleukin-2 and stem cell factor in patients with AIDS or AIDS-related malignancies.
- Determine the immune status of patients treated with this regimen.
OUTLINE: This is a multicenter, dose-escalation study of stem cell factor.
Patients receive interleukin-2 (IL-2) subcutaneously (SC) six days a week and stem cell factor SC three times a week for 8 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of stem cell factor until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 3 patients receives treatment at the MTD.
Patients are followed every 2 weeks for 1 month.
PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263-0001
- Roswell Park Cancer Institute
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
- Diagnosis of HIV-1 by ELISA, Western blot, polymerase chain reaction, or other documentation
Must have had 1 of the following AIDS-defining illnesses:
- Opportunistic infection
- Opportunistic malignancy (excluding CNS involvement)
- CD4 T-cell count less than 200/mm^3 (but currently greater than 20/mm^3)
- Receiving antiretroviral therapy
No concurrent Kaposi's sarcoma
- Prior Kaposi's sarcoma in complete response allowed
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 80-100%
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count greater than 1,000/mm^3*
- Hemoglobin at least 10 g/dL*
- Platelet count greater than 50,000/mm^3* NOTE: *Transfusions and growth factors allowed in order to increase or maintain counts
Hepatic
- No major hepatic dysfunction evidenced by encephalopathy, ascites, or varices
- Bilirubin no greater than 2 mg/dL
- INR no greater than 1.5
Renal
- Not specified
Cardiovascular
- No prior angioedema
- No uncontrolled hypertension (i.e., diastolic blood pressure greater than 115 mmHg)
- No unstable angina
- No New York Heart Association class III or IV heart disease
- No congestive heart failure
- No coronary angioplasty within the past 6 months
- No myocardial infarction within the past 6 months
- No uncontrolled atrial or ventricular cardiac arrhythmia
Pulmonary
- No history of seasonal or recurrent asthma within the past 10 years
- No concurrent asthmatic symptoms (e.g., wheezing) related to a current respiratory tract infection
Immunologic
- No prior positive allergy test (skin or radioallergosorbent test) for insect venoms
- No known allergy to E. coli-derived products
- No prior anaphylactic events manifested by disseminated urticaria, laryngeal edema, and/or bronchospasm
- Drug allergies manifested solely by rash and/or urticaria allowed
- No recurrent urticaria (isolated episode of urticaria allowed)
- No other active uncontrolled infection (including one with current symptoms of bronchoconstriction)
No fever of 38.2° C or higher
- Fevers due to B symptoms allowed
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior or concurrent CNS malignancy
- No poorly controlled diabetes
- No other significant nonmalignant disease
- No other malignancy except those in stable partial response or stable complete response (no evidence of progressive disease for at least 8 weeks after therapy for the malignancy)
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Hematopoietic in Patient Characteristics
- No prior stem cell factor
- No concurrent interleukin-11 for thrombocytopenia
Chemotherapy
- No concurrent chemotherapy for malignancy
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No concurrent enrollment on any other protocol utilizing an investigational drug
- No concurrent beta adrenergic blocking agents
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Zale P. Bernstein, MD, Roswell Park Cancer Institute
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RP 99-11
- RPCI-RP-9911
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på aldesleukin
-
National Cancer Institute (NCI)AvslutadMetastaserande melanom | NjurcellscancerFörenta staterna
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); Chiron CorporationAvslutad
-
Blumenthal Cancer Center at Carolinas Medical CenterOkänd
-
Cancer Biotherapy Research GroupOkändLungcancerFörenta staterna
-
St. Anna KinderkrebsforschungOkänd
-
National Cancer Institute (NCI)Avslutad
-
Cancer Biotherapy Research GroupOkänd
-
University of Southern CaliforniaNational Cancer Institute (NCI)AvslutadOspecificerad fast tumör för vuxen, protokollspecifikFörenta staterna
-
European Organisation for Research and Treatment...AvslutadLeukemiFrankrike, Belgien, Nederländerna, Italien, Österrike, Kroatien
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer InstituteAvslutadMalignt melanomFörenta staterna